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Abstract
A significant number of children with T-lineage acute lymphoblastic leukemia (T-ALL) fail to
respond to therapy and experience early relapse. CD99 has been shown to be overex-
pressed on T-ALL cells and is considered to be a reliable detector of the disease. However,
the relevance of CD99 overexpression in ALL has not been investigated in a functional con-
text. The aim of this study was to investigate the functional capacity of CD99+ cells in child-
hood ALL and determine the suitability of CD99 as a therapeutic target. Flow cytometric
analyses confirmed higher expression of CD99 in ALL blasts (81.5±22.7%) compared to
normal hemopoietic stem cells (27.5±21.9%) and T cells (3.1±5.2%, P0.004). When ALL
cells were sorted and assessed in functional assays, all 4 subpopulations (CD34+/CD99+,
CD34+/CD99-, CD34-/CD99+ and CD34-/CD99-) could proliferate in vitro and establish leu-
kemia in NSG mice. Leukemia propagating cell frequencies ranged from 1 in 300 to 1 in
7.4x104 but were highest in the CD34+/CD99- subpopulation. In addition, all four subpopu-
lations had self-renewal ability in secondary NSG mice. Cells in each subpopulation con-
tained patient specific TCR rearrangements and karyotypic changes that were preserved
with passage through serial NSG transplants. Despite high levels of CD99 antigen on the
majority of blast cells, leukemia initiating capacity in vivo was not restricted to cells that
express this protein. Consequently, targeting CD99 alone would not eliminate all T-ALL
cells with the ability to maintain the disease. The challenge remains to develop therapeutic
strategies that can eliminate all leukemia cells with self-renewal capacity in vivo.
Introduction
T-cell acute lymphoblastic leukemia (T-ALL) is a genetically heterogeneous cancer, with 20%
of childhoodpatients and the majority of adult patients dying from resistant or relapsed dis-
ease.[1] Leukemia propagating cells (LPC) have been a topic of much investigation in recent
years; they can self-renew to maintain the disease and some are resistant to current chemother-
apeutic agents,[2–6] so these cells have the potential to cause relapse. LPC identified using
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immune deficientmouse models are diverse in terms of expression of CD34, CD1a, CD4 and
CD7 antigens in both pediatric and adult T-ALL.[2–6] Since none of these markers are specific
for LPC, distinguishing them from normal cells can be difficult.
Minimal residual disease (MRD) detection is a well-established tracking tool to assess thera-
peutic response. MRD levels during remission induction have become the most important
prognostic indicator in ALL.[7–12] Consequently, they have been incorporated into global
treatment protocols for risk assignment and selection of appropriate therapy (e.g. UKALL
2011, AIEOP-BFM ALL 2009, TOT XVI). In recent years, flow cytometric (FCM) panels have
been developed to identify residual leukemia in a faster and more cost effectivemanner with
good concordance (75–95%) with PCR-based analyses.[13, 14] EuroFlow antibody panels for
standardized T-ALL diagnosis and MRD assessment[15] aim to discriminate T-ALL blasts
from normal hemopoietic cells. CD99, a 32-kD transmembrane protein, is a leukemia associ-
ated phenotypemarker used for the positive diagnosis of T-ALL. It is used with nuclear TDT,
CD5, CD10 and CD1a as a panel that can discriminate T-ALL cells from normal hemopoietic
cells.[15] Surface CD99 expression is high on pediatric T-ALL cells[16, 17] and absent on nor-
mal T cells. However, unlike some of the other markers in this panel, the relevance of CD99
overexpression has not been investigated in a functional context. Consequently, its role in leu-
kemogenesis and potential as a therapeutic target are not known. Over-expression of cell sur-
face antigens on leukemia cells has been exploited for therapeutic purposes e.g. Blinatumomab
[18, 19] and CAR-T cell antigens against CD19 in B cell precursor (BCP) ALL.[20–22] Unfor-
tunately, there is a lack of such targeted therapies for T-ALL. In this study we have investigated
the expression of CD99 on LPCs that we have previously shown to be CD34+/CD7+, CD34+/
CD7- or CD34- [5, 6] and assessed the functional capacity of cells sorted on the basis of surface
CD99 expression in vitro and in vivo.
Materials and Methods
Sample sources
BM cells from children (median age, 6 years; range, 2–17 years) with T-ALL at presentation or
relapse were obtained with written consent from parents or guardians and with approval of
University Hospitals Bristol NHS Trust and the National Research Ethics Committee London-
Brent. Detailed characteristics of the patient samples are shown in Table 1, below, and Table A
in S1 File. Samples were selected on the basis of availability of material for study only. Normal
Table 1. Patient sample characteristics.
% Nucleated cells
ID Karyotype Age (y) Sex Disease status MRD risk status CD34+/CD99+ CD34+/CD99- CD34-/CD99+ CD34-/CD99-
1 iso 9, +4 15 M Relapse Risk 1.70 0.80 95.00 2.50
2 t(11;14) 2 M Relapse Low 1.19 0.22 91.45 7.14
3 t(9;16),+7,-9 5 M Relapse Risk 2.70 1.80 78.90 16.60
4 46 XY 17 M Diagnosis Risk 58.10 1.34 29.30 11.26
5 t(1;14) 10 M Diagnosis Low 0.42 0.02 96.28 3.28
6 del 6q 15 M Diagnosis Risk 90.60 0.81 3.97 4.62
7 +1, del 6, del11 2 F Diagnosis N/A 0.09 0.01 64.7 35.2
8 46 XY 3 M Diagnosis Risk 0.11 0.07 87.5 12.32
9 complex 6 M Diagnosis Low 0.01 0.01 90.7 9.28
N/A, not available.
doi:10.1371/journal.pone.0165210.t001
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BM (NBM) and peripheral blood (PB) samples were obtained from consented healthy donors.
Cells were separated using Ficoll-Hypaque (Sigma-Aldrich, Poole, UK), mononuclear cells
(MNC) were suspended in Iscoves modifiedDulbeccosmedium (IMDM; Invitrogen, Paisley,
UK) with 90% fetal calf serum (FCS; Invitrogen) and 10% dimethyl sulfoxide (DMSO;Manor
Park Pharmaceuticals, Bristol, UK) and stored in liquid nitrogen. Mean viability of samples on
thawing was 83±17% for ALL samples and 71±17% for normal samples.
Flow cytometry
Thawed human BM cells were labelledwith the following antibodies from BD Biosciences
(Oxford, UK), unless otherwise specified; anti-CD34 (clone 8G12)-APC and anti-CD38 (clone
HB7)-PE or anti-CD3 (clone BW264/56)-FITC (Miltenyi Biotec, Surrey UK) and 7AAD (Sigma-
Aldrich, Poole UK). ThawedMNC from 9 primary T-ALL cases were stained with anti
CD34-APC, anti-CD7 (cloneM-T701)-FITC, anti-CD99 (clone TÜ12)-PE and 7AAD. Cells
were analyzed and sorted using a BectonDickinson Influx cell sorter and BD Sortware version 1
(BD Biosciences), as outlined in Fig A in S1 File. Cells were initially gated on low forward and
side scatter, excluding doublets and fluorescenceminus one controls were used to set sort gates.
Microarray analyses
Gene expression analysis of 5 normal BM and 5 T-ALL primary samples was performed using
AgilentWhole Human GenomeOligoMicroarrays (Miltenyi Biotec, Germany). Normal CD34+/
CD38- hemopoietic stem cells (HSC) and CD34+/CD7+, CD34+/CD7-, CD34-/CD7+, CD34-/
CD7- T-ALL subpopulations were sorted for whole genome array (WGA) analysis. Unsorted BM
MNC and bulk T-ALL cells from the same respective sample cohorts were also used for WGA
analyses. Cells were lyzed using SuperAmp Lysis Buffer according to the manufacturer’s instruc-
tions (Miltenyi Biotec). RNA amplification, cDNA preparation and hybridization were per-
formed by Miltenyi Biotec as was subsequent gene-expression analysis using AgilentWhole
Human GenomeOligoMicroarrays. Fluorescence signals were detected using Agilent’s Microar-
ray Scanner System (Agilent Technologies) and analyzed with the Agilent Feature Extraction
Software. The entire data set of signal intensities was normalized by dividing the intensity value
of each sample by the overall median, transformed to log scale and median centred. Differential
gene expression analysis was performedon comparisons betweenT-ALL LPC versus normal
HSC and bulk T-ALL versus bulk normal BM.Microarray data are available in the ArrayExpress
database (www.ebi.ac.uk/arrayexpress) under accession number E-MTAB-4006.
Suspension culture assay
Suspension cultures were initiated with unsorted ALL cells or with sorted subfractions at up to
5x105 cells/mL, in IMDM supplemented with interleukin (IL)-3 (20ng/ml), IL-7 (10ng/ml) and
stem cell factor (50ng/ml, all R&D systems, Abingdon UK). Cultures were maintained for up
to 6 weeks with weekly half media changes. Cells removed during the media changes were used
to determine viability and absolute counts by flow cytometry and for cytogenetic analyses by
FISH, as describedpreviously.[2]
In vivo studies
In vivo experiments were carried out in accordance with the Animals (Scientific Procedures)
Act under licenses granted by the United KingdomHome Office (PPL 30/3113) and all efforts
were made to minimize suffering, including killing via a schedule 1 method at the first sign of
disease symptoms. NSGmice were bred and maintained at the University of Bristol Animal
Relevance of CD99 Overexpression in T-ALL
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ServiceUnit. Mice were not preconditioned prior to inoculation.Cells were resuspended in
0.3mL IMDM+ 5% human serum albumin and injected into the lateral tail veins of 6–8 week old
mice. Unsorted cells and sorted cell populations were inoculated at a range of doses. Animals
were monitored weekly for the presence of human cells in PB aspirates, maintained for up to 20
weeks and killed electively or as soon as they began to exhibit clinical symptoms of disease. The
gross anatomy was inspected and femoral BM samples were removed for FCM and cytogenetic/
histologic analyses. FCM analyses of PB and BM from xenografts were undertakenusing anti-
bodies against human CD7, CD19, CD34, CD45, CD99 and murine CD45 (all BD Biosciences).
Aliquots of cells fromNSG BMwere plated onto slides for cytogenetic or morphological analysis.
Cells harvested from BM of some engraftedmice were used for serial transplantation experi-
ments. These cells were not enriched for any particular phenotype before evaluation in sequen-
tial xenografts. Details of the number of cells inoculated into secondary recipients are provided
in Table C in S1 File.
Identification of clonal receptor gene rearrangements
SortedALL subfractions and cells recovered from BM of engraftedNSGmice were screened
for the presence of T-cell receptor (TCR) rearrangements (TCRG, TCRD, and TCRB). DNA
was extracted using QIAamp DNA Micro kit (QIAGEN, Crawley, United Kingdom). The poly-
merase chain reaction (PCR) primers and conditions used were as describedpreviously.[2]
PCR products were subjected to heteroduplex analysis, cloned and the monoclonal products
were sequenced. Each rearrangement was characterized by comparison of sequences with
germline sequences contained in online database www.imgt.org/IMGT_vquest/share/textes/.
Cytogenetic analyses
Cytogenetic analysis by fluorescence in situ hybridization (FISH) was performed on samples at
diagnosis, on cells harvested from cultures and cells harvested fromNSGmarrow by Bristol
Genetics Laboratory, SouthmeadHospital. At least 50 nuclei per sample were scored on prepa-
rations from cultured cells and those harvested from NSGmice.
Statistical analyses
Analysis of variance (ANOVA) followed by Tukey’s post-hoc testing was used to compare
CD99 antigen expression in the different cell sources and the proliferation of subpopulations
in suspension culture. ANOVA and Tukey post-hoc tests were also used to identify significant
differences in gene expression between groups of samples. Fold-change in gene expression
between 2 samples was equivalent to their log2 intensity ratio. Bulk T-ALL gene expression
was directly compared to BMMNC and that of each LPC subpopulation was compared to
HSC. LPC frequencies were determined by Poisson statistics using L-Calc software (StemCell
Technologies Inc). Matched paired T-tests were used to compare engraftment levels between
primary and secondaryNSG recipients.
Results
BM samples from 9 children diagnosedwith T-ALL and normal healthy donors were studied
(Table 1). Initially CD99 expression, as determined by flow cytometry, was compared in nor-
mal BMMNC, CD34+/CD38- HSC, CD3+ T cells and T-ALL blasts (Fig 1A). The proportion
of CD99+ cells was significantly higher in T-ALL (median 90.5%, range 27.4–97%) than BM
MNC (22%, 6.8–51.9%), HSC (22%, 10–62.7%) and CD3+ T cells (0.55%, 0.14–15.9%, P0.004).
In normal donor samples, the proportion of CD99+ cells was significantly lower in CD3+ T cells
Relevance of CD99 Overexpression in T-ALL
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compared to HSC andMNC (P0.007). Subsequently, we investigated expression of CD99 in
known LPC subpopulations[5, 6] from these T-ALL cases. The highest proportions of CD99+
cells were found in the CD34+/CD7+ (median 91.7%, range 52–99.6%) and CD34-/CD7+ LPC
populations (97.3, 40–99.3%, Fig 1B). Significantly fewer CD99+ cells were detected in the
CD34+/CD7- and CD34-/CD7- subpopulations with median values of 29.9 and 21.7%, respec-
tively (P0.009). However, with the exception of pts 2 and 8, the proportions of CD99+ cells
detectable in the CD34+/CD7- and CD34-/CD7- subpopulations were above 20%. In order to
compare individual patient samples, the proportions of CD99+ cells in each LPC subpopulation
are also shown (Fig 1C).Whilst there are clear differences between cases, in general the propor-
tion of CD99+ cells in the CD34+/CD7+ subpopulation was similar across the cohort. Likewise,
expression of CD99 was similar in the CD34-/CD7+ subpopulation, with the exception of pts 3
and 6. To further investigate this CD99 overexpressionWGA analyses were performedon sorted
subpopulations from 5 cases, based on expression of CD34 and CD7 and unsorted bulk leukemia
cells. Results were compared with data from normal BMMNC and CD34+/CD38- HSC, (www.
ebi.ac.uk/arrayexpress, accession number E-MTAB-4006). CD99 was expressed at higher levels
in ALL cells and some LPC subpopulations compared to BMMNC and HSC (Fig 1D), although
the differences were not significant.Other genes associatedwith T-ALL, such as CD2 and CD5,
were 2 and 7-fold overexpressed, respectively, compared to normal BMMNC.
As the FCM analyses demonstrated CD99 was expressed on all subpopulations that we have
previously shown to have LPC capacity, we investigated whether its expression was important
for proliferation in vitro and in vivo. Since CD99 expression co-segregatedwith CD7 in most
cases, CD34 and CD99 subpopulations were purified for functional analyses. On sorting, the
CD34+/CD99+ and CD34-/CD99+ subpopulations represented the majority of leukemia blasts
Fig 1. Expression of CD99 in T-ALL and normal hemopoietic cells. (A) Expression of CD99 antigen
was assessed by flow cytometry in BM samples from 9 T-ALL cases and BM MNC, CD34+/CD38- HSC and
CD3+ T cells from 5–9 healthy donors. Lines represent median values, ** P0.007, ****P<0.0001. (B)
Expression of CD99 in sorted LPC subpopulations from this T-ALL cohort. Lines represent median
values, * P = 0.02, ** P0.009. (C) Stacked bar chart showing expression of CD99 in CD34/CD7 LPC
subpopulations in individual cases. (D) Gene expression in BM samples from 5 T-ALL cases (pts 2, 4, 7, 8, 9)
and from 5 healthy donors were analyzed using Agilent Whole Genome Oligo microarrays. Data shows side
by side comparisons of median centered normalized log2 signal intensities. Boxes represent the range of
expression and the horizontal lines represent the median.
doi:10.1371/journal.pone.0165210.g001
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(31.5±43% and 62.2±44%, respectively), while the CD34+/CD99- subpopulation was the small-
est (0.40±0.7%, Fig 2A). After 3 weeks in culture, the majority of proliferating cells were derived
from the CD34+/CD99- and CD34-/CD99- subpopulations. Cells derived from the CD34+/
CD99- subpopulation accounted for the majority of proliferating cells at weeks 5 (68.2±16%)
and 6 (60.0±15%, P = 0.02). Greatest expansion was observed in cultures of CD34+/CD99- cells
Fig 2. In vitro proliferation of CD34/CD99 subpopulations. (A) T-ALL cells (pts 1, 4–6 and 9) were stained with
antibodies against CD34, CD99 and CD7, the subpopulations were sorted based on CD34/CD99 expression and
the proliferative ability was assessed in long-term culture. Cultures were maintained with weekly half-media
changes. Absolute cell counts, derived from each sorted population and unsorted controls, were determined by
flow cytometry at weeks 1, 3, 5 and 6. (A) Proportions of total viable cells, represented by each sorted population,
were calculated using absolute cell count values at the time points indicated. Data expressed as mean ± SD, *
P = 0.02, ** P0.005, *** P = 0.0004. (B) Maintenance and expansion of unsorted cells and each sorted
subpopulation over the time course of the culture. NC, nucleated cells.
doi:10.1371/journal.pone.0165210.g002
Relevance of CD99 Overexpression in T-ALL
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(4.6–1798 fold, P0.02) from 7.5x103 up to 2.6x106 cells at week 6 (Fig 2B). Expansion was
also observed in cultures of unsorted cells from 1x105 to>7x105 and CD34-/CD99- cells (4.7
fold at week 3, 2.5 fold at week 6). In cultures of CD99+ cells, absolute cell counts initially
declined but recovered to 57% (CD34+/CD99+ subpopulation) or 70% (CD34-/CD99+ subpop-
ulation) of initial starting cell numbers by week 6. FISH analyses confirmed the cultured cells
from each sorted subpopulation retained the patient specific karyotypic abnormalities and the
frequency of aberrant cells (20–100% FISH+) was similar to that reported at diagnosis, con-
firming proliferation of cells derived from the leukemia clone.
Cells from 5 cases were sorted based on expression of CD34 and CD99 (detailed in Table 1)
and inoculated into NSGmice at a range of doses to estimate the frequency of LPC (Table 2).
LPC were detected in each subpopulation examined. The frequencies varied from 1 in 1300 to
1 in 7.4x104 but were highest in the CD34+/CD99- subpopulation. As the number of sorted
cells available limited the extent of the dilution analysis, these LPC frequencies are likely to be
an underestimate.
Leukemia engraftment in NSGmice was achieved using unsorted cells (0.7–98%) and with
each sorted subpopulation, CD34+/CD99+ (2–99%), CD34+/CD99- (3–85%), CD34-/CD99+
(3–99%) and CD34-/CD99- (2–93%, Fig 3A). In most cases there was no difference in the rate
of engraftment between the different subpopulations, with engraftment achieved 3–12 weeks
from inoculation. This was despite injecting 2–3 log fewer CD99- cells. In pt 4, engraftment of
both CD34+/CD99- and CD34-/CD99- cells was delayed by 3 weeks compared to recipients of
CD34+/CD99+ and CD34-/CD99+ cells. However, up to 2 log fewer CD99- cells were inocu-
lated. All 4 subpopulations also had self-renewal capacity as demonstrated by engraftment of
secondaryNSG recipients (Fig 3B). Higher levels of leukemia engraftment were observed in
the secondary animals compared to the primary recipients, despite injecting lower numbers of
cells in some cases (P0.04). Time to leukemia onset was reduced compared to the primary
animals (2–9 weeks) and in pt 4, the engraftment delay betweenCD99+ and CD99- subpopula-
tions was reduced to 12 days. In most cases, regardless of the subpopulation inoculated, the
immunophenotype of harvestedNSG BM cells was similar to that of the patients at diagnosis
(Table A in S1 File)), with loss of CD34 and gain of CD99 in pts 2, 3 and 9 and gain of both
markers in pt 6 (Table B in S1 File). In pt 4 there were no substantive changes in immunophe-
notype with passage through NSGmice, reflecting the mixed expression of these antigens in
the patient at diagnosis. Patient specific TCR rearrangements were conservedwith passage
through NSGmice (Table C in S1 File) and FISH analyses showed the cells also had the patient
specific karyotypic aberrations (66–100%), confirming engraftment of leukemia cells and dem-
onstrating each subpopulation had self-renewal capacity.
Discussion
While modern treatment protocols have vastly improved survival rates for childhood leukemia,
the 5 year survival rate for T-ALL (~85%) remains worse than that of BCP-ALL.[23] The
majority of relapses occur during treatment and the prognosis for these patients is poor, with
<25% surviving.[23, 24] A better understanding of the biology of the diseasemay permit the
development of more targeted, less toxic therapies. Over-expression of certain antigens on ALL
cells enables accurate diagnosis, classification, diseasemonitoring and importantly, indicates
potential targets for therapy. While several antibody based therapies have been developed for
BCP-ALL, options for T-ALL therapy are limited. Lack of specificity of somemarkers and
clonal heterogeneity within patient cells are important considerations in the development of
targeted therapeutics. In the present study we sought to investigate the relevance of CD99
over-expression in childhoodT-ALL.
Relevance of CD99 Overexpression in T-ALL
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The data from FCM and genetic analyses confirmedCD99 expression is higher in T-ALL
cases than in normal BM cells.[16, 17] In addition, the FCM findings are consistent with previ-
ous reports, using the same monoclonal antibody clone, identifyingCD99 as a useful discrimi-
nator of T-ALL blasts from normal T lymphocytes.[15, 16] During T cell development CD99 is
downregulated on normal T-cells with increasing expression of surface CD3.[25] CD99 was
highly expressed in the current patient cohort, regardless of prognostic indicators or MRD risk
status. One of the 9 cases studied, pt 3, a relapse sample classed as highMRD risk, had
Table 2. Frequency of LPC in CD34/CD99 subpopulations.
Population Dose Sample ID No. engrafted / No. injected LPC frequency (95% CI) % FISH +
Unsorted 5x106 2 1/1 1: 1.3x105 (0.4x105–3.8x105) 72–100
4x106 6,9 3/3
2x106 4,9 3/3
1x106 2,4,9 4/4
5x105 3,6,9 3/3
1x105 3,9 1/2
5x104 2,4,9 1/3
1x104 3 0/1
CD34+/CD99+ 4x106 6 1/1 1: 3.3x104 (0.1x105–1.1x105) 66–100
2x106 4 1/1
1.5x105 9 1/1
1x105 4,6 3/4
3x104 2 1/1
1x104 2 1/1
3x103 3 1/1
CD34+/CD99- 1x105 9 1/1 1: 1.3x103 (0.3x103–5.6x103) 75–100
6x104 4 1/1
5x104 2,4 2/2
3x104 4 1/1
1x104 3 1/1
2.3x103 3,6 2/2
1x103 6 0/1
CD34-/CD99+ 2.5x106 4 1/1 1: 5.6x104 (0.2x105–1.6x105) 70–100
2.2x106 9 1/1
1.6x106 2 1/1
1x106 4,9 3/3
5x105 2 1/1
4x105 3 1/1
3x105 6 1/1
1x105 3,4,6,9 3/4
5x104 2 1/1
2x106 2 1/1 1: 7.4x104 (0.3x105–1.6x105) 81–100
1x106 4,9 2/2
6x105 4 1/1
CD34-/CD99- 2x105 3 1/1
1x105 2,3,4,6,9 5/7
5x104 2,3 1/2
LPC frequencies calculated using L-Calc Software
doi:10.1371/journal.pone.0165210.t002
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comparatively low expression of CD99 (27%). This is also consistent with reported frequencies
of lower CD99 expression in ~15% of childhoodT-ALL cases.[16]While CD99 gene expres-
sion was not significantly higher, in a smaller cohort of patients, compared to normal BM sam-
ples, genes for other leukemia associated phenotype markers used in the EuroFlow FCM
T-ALL MRD panels, including CD2 and CD5, were overexpressed in these cases.[15] Gene
expression analyses of LPC are extremely challenging, due to limiting cell numbers and this
study represents the first report onWGA analyses in T-ALL LPC populations.
Fig 3. NSG engrafting capacity of CD34/CD99 subpopulations. T-ALL cells from 5 cases (pts 2, 3, 4, 6, 9) were sorted
based on expression of CD34/CD99 and the repopulating capacity of each sorted population was assessed in NSG mice
(A). Each patient is represented by a specific symbol and each symbol depicts the engraftment detected in the BM of an
individual mouse by flow cytometric analysis, measured by anti-human CD45 antibody. (B) Cells harvested from the BM of
some engrafted primary recipients were inoculated into secondary NSG recipients. The X axes depict the number of cells
inoculated from each sorted subpopulation (A) or from primary xenograft source (B).
doi:10.1371/journal.pone.0165210.g003
Relevance of CD99 Overexpression in T-ALL
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In order to understand the relevance of this overexpression of CD99 and to determine
whether it plays a role in leukemogenesis, it was essential to assess the functional capacity of
these cells in vitro and in vivo. We have previously shown that blasts from both BCP- and T-ALL
cases can bemaintained in culture for extended periods of time with no loss of karyotype or TCR
rearrangements.[2, 5] Data from the long-term suspension cultures and serial NSG passage indi-
cate that expression of CD99 is not a prerequisite for proliferation in vitro or for leukemia propa-
gating capacity in vivo. While the levels of engraftment varied amongst patient samples and the
subpopulations inoculated, engraftment was achieved in every case with both CD99+ and CD99-
cells, even though the majority of blast cells in these cases expressed CD99. Likewise, both CD34+
and CD34- cells could engraft, regardless of expression of CD99, despite 3 of the 5 patients having
a CD34- immunophenotype. The lower levels of engraftment observedwith CD99- cells is likely
to be a result of lower numbers of these cells in the inocula, rather than reduced engrafting capac-
ity. In fact, the analyses of LPC frequency indicate it was higher in the CD34+/CD99- subpopula-
tion in this patient cohort. In each sample studied, the phenotype of the inoculated cells changed
in vivo to produce T-ALL in NSGmice with an immunophenotype similar to that of the patient
at diagnosis, with increased expression of CD99 in recipients of CD99- subpopulations. Such
immunophenotypic changes following xenotransplantion of T-ALL cells are consistent with pre-
vious reports using NSG and NOD/SCIDmice.[2, 5] All the sorted subpopulations had self-
renewal capacity and engraftment was higher and leukaemia onset more rapid in the secondary
animals. Furthermore, the patient specific karyotypes and TCR gene rearrangements were also
retained with passage throughNSGmice, confirming engraftment of leukemia cells. These data
suggest that targeting CD99 alone, or in combination with CD34/CD7, would not be an effective
approach to eradicating cells with leukaemia initiating capacity in vivo.
In addition, the findings indicate that absence of CD99+ cells during therapy may not mean
lack of residual disease. However, the established practice of multi-panel FCMMRD analyses
should mitigate the risk of false negative results. A previous study reported loss of both CD99
and TdT during therapy.[17] The authors suggested this could be due to selective survival of
CD99- subpopulations or downregulation of CD99 on surviving cells. While our study did not
investigate antigenic changes during therapy, we did not observe loss of CD99 during passage
in NSG. As our data demonstrate that both CD99+ and CD99- subpopulations were capable of
self-renewal, survival of only CD99- cells following induction therapy, as suggested by Roshal
et al, [17] would still leave a population of cells potentially capable of causing relapse. Such a
phenomenon has been reported in patients with BCPALL relapsing with CD19- leukemias
after administration of CD19-CAR-T cells, with lymphoid to myeloid phenotypic switching in
some cases.[21, 22, 26]. The current findings add to the evidence of the diverse nature of this
malignancy and are further proof that multiple LPC subpopulations exist in childhoodT-ALL,
as has been described for BCPALL.[5, 27, 28] In order to improve outcomes for T-ALL it will
be necessary to target all cells that have leukemia propagating capacity in vivo and not just
those that represent the majority of blast cells in patients.
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